Tsung-Hsun Yu

Tsung-Hsun Yu

Auto-generated profile, based on publicly available information

Tsung-Hsun Yu

Brain Research Center, National Yang Ming Chaio Tung University, Taipei 112, Taiwan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Clinical Nuclear Medicine
Verified
Journal Article
Open access
SYSkye Hsin-Hsien Yeh
Skye Hsin-Hsien Yeh
CTChi-Jung Tsai
Chi-Jung Tsai
TYTsung-Hsun Bs Yu
Tsung-Hsun Bs Yu
YCYung-Hsiao Chiang
Yung-Hsiao Chiang
SLShinn-Zong Lin
Shinn-Zong Lin
WHWen-Sheng Huang
Wen-Sheng Huang
Objectives: Neuroimaging studies in the past 20 years have documented an age-related decline in striatal dopamine transporters (DATs), which is a marker of dopaminergic neurodegeneration; however, concerns about ethnic variations in the decline in DAT with age have not been addressed. The purpose of this study was to assess the rate of striatal DAT loss in healthy Taiwanese adults using kit-based 99mTc-TRODAT-1, a radioligand for DAT SPECT. Patients and Methods: Fifty healthy subjects (mean age ± SD, 63 ± 12 years; range, 30–80 years) were studied. 99mTc-TRODAT-1 was prepared from a lyophilized kit. Brain DAT SPECT imaging was acquired between 165 and 195 minutes postinjection (~740 MBq or 20 mCi) using a dual-head camera equipped with fan-beam collimators (Helix SPX; GE). Specific uptake in the striatum (ST), caudate nucleus (CA), and putamen (PU) were calculated from reconstructed transaxial slices at the level of maximal striatal activity. Occipital cortices were used as reference areas. Data were presented as specific binding ratios. Results: Age had a significant moderate to large negative effect on striatal DAT, which declined by −25.7% ± 6.10% between the ages of 30 and 80 years, equivalent to 6.4% loss per decade. The rates of decline in the CA and PU were 6.9% and 7.3% per decade, respectively. Conclusions: This study suggests ethnic variations may not significantly affect the age-related decline in DAT. The data generated in this study could also be used as a reference to estimate DAT loss/occupancy in patients with DAT-related diseases.

4 June 2025 in Clinical Nuclear Medicine
Verified
Journal Article
Open access
SYSkye Hsin-Hsien Yeh
Skye Hsin-Hsien Yeh
YLYung-Shuan Lin
Yung-Shuan Lin
Wei-Ju LeeWei-Ju Lee
Wei-Ju Lee
WCWen-Yi Chang
Wen-Yi Chang
TYTsung-Hsun Yu
Tsung-Hsun Yu
JFJong-Ling Fuh
Jong-Ling Fuh
Purpose: This multiyear study aimed to investigate the relationship between TSPO expression and cognitive decline in Alzheimer disease (AD) using [18F]FEPPA PET imaging. We integrated this imaging data with 12 comprehensive clinical measures to assess disease severity and progression in AD, mild cognitive impairment (MCI), and healthy controls (HC). Methods: A total of 39 participants, including 17 AD patients, 9 MCI patients, and 13 healthy controls, underwent [18F]FEPPA PET imaging and neuropsychological evaluations. Quantitative analysis was performed to determine the total distribution volume (VT) ratios in 8 brain regions, such as the frontal lobe, parietal lobe, and hippocampus. Cognitive function was assessed using a battery of tests, including the Mini-Mental State Examination (MMSE), Rey Auditory Verbal Learning Test (RAVLT), and Trail Making Test. Results: AD patients exhibited significantly elevated VT ratios in the frontal lobe, parietal lobe, and hippocampus compared with HC (P < 0.01). Notably, MCI patients had higher VT ratios than both HC and AD in the temporal and occipital lobes (P < 0.05), indicating early neuroinflammatory involvement. Moderate to strong correlations (R 2 values: 0.45–0.68) were observed between TSPO expression and cognitive performance. Conclusions: The findings of this study provide preliminary support for the use of [18F]FEPPA PET in assessing neuroinflammation related to cognitive decline in AD. Moreover, our results indicate that combining imaging techniques with neuropsychological assessments may offer a useful approach for monitoring disease progression and detecting early inflammatory changes in individuals with MCI.

9 December 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
WHWen Tsung Ho
Wen Tsung Ho
TYTsung-Hsun Yu
Tsung-Hsun Yu
WCWen-Hung Chao
Wen-Hung Chao
BWBao-Yen Wang
Bao-Yen Wang
YKYu-Yeh Kuo
Yu-Yeh Kuo
SYSkye Hsin-Hsien Yeh
Skye Hsin-Hsien Yeh
Hydrogen/oxygen-generating biomaterials, a new trend in regenerative medicine, generate and supply hydrogen/oxygen to increase the local levels of hydrogen/oxygen to support tissue healing and regeneration. In this study, we carefully defined a strategic plan to develop a gas-permeable layer suitable for use in sanitary products that is capable of supplying hydrogen or oxygen in situ using calcium hydroxides as chemical oxygen sources. In vitro physicochemical evaluations of hydrogen- and oxygen-generation efficiency were performed to determine the amount of hydrogen and oxygen produced. An in vivo permeation study was conducted to assess biological parameters, including blood oxygen (O2) and hydrogen (H+) levels. The stress hormone corticosterone and inflammation marker interleukin 6 (IL-6) were also quantified. The hydrogen/oxygen-generating patch (HOGP) continuously generated H+ or O2 for up to 12 h after activation by water. An in vivo evaluation showed blood H+ peaked at 2 h after application of the HOGP and then progressively decreased until the end of study (24 h), whereas oxygen content (O2(ct)) and oxygen saturation (SO2(SAT)) continuously increased up to 6 h. Hematological and electrolyte parameters did not significantly change compared to baseline. Wearing the stretch fabric used to secure the patch did not significantly increase serum corticosterone or interleukin 6 (IL-6) in the animals. This novel design of a hydrogen/oxygen-generating biomaterial for supplying topical H+/O2 may hold potential for increasing in situ or circulating H+/O2 levels to improve healthcare outcomes.

Verified
Journal Article
Open access
PDF file
TCTsai Chi-Jung
Tsai Chi-Jung
CCChiu Chuang-Hsin
Chiu Chuang-Hsin
YKYu-Yeh Kuo
Yu-Yeh Kuo
WHWen-Sheng Huang
Wen-Sheng Huang
TYTsung-Hsun Yu
Tsung-Hsun Yu
KMKuo-Hsing Ma
Kuo-Hsing Ma
Numerous studies have confirmed that 3,4-Methylenedioxymethamphetamine (MDMA) produces long-lasting changes to the density of the serotonin reuptake transporter (SERT). Amitriptyline (AMI) has been shown to exert neuroprotective properties in neuropathologic injury. Here, we used a SERT-specific radionuclide, 4-[18F]-ADAM, to assess the longitudinal alterations in SERT binding and evaluate the synergistic neuroprotective effect of AMI in a rat MDMA model. In response to MDMA treatment regimens, SERT binding was significantly reduced in rat brains. Region-specific recovery rate (normalized to baseline) in the MDMA group at day 14 was 71.29% ± 3.21%, and progressively increased to 90.90% ± 7.63% at day 35. AMI dramatically increased SERT binding in all brain regions, enhancing average ~18% recovery rate at day 14 when compared with the MDMA group. The immunochemical staining revealed that AMI markedly increased the serotonergic fiber density in the cingulate and thalamus after MDMA-induction, and confirmed the PET findings. Using in vivo longitudinal PET imaging, we demonstrated that SERT recovery was positively correlated with the duration of MDMA abstinence, implying that lower SERT densities in MDMA-induced rats reflected neurotoxic effects and were (varied) region-specific and reversible. AMI globally accelerated the recovery rate of SERT binding and increased SERT fiber density with possible neuroprotective effects.